Selected publications of the first funding period at a glance
PIs of CRC1479 are first or last author and CRC1479 funding is indicated in the acknowledgement.
- Vinnakota JM et al. Nature Cancer 2024 doi: 10.1038/s43018-024-00764-7
- Schmitt M et al. Nature 2022 doi: 10.1038/s41586-022-05426-1
- Masuda T et al. Nature 2022 doi: 10.1038/s41586-022-04596-2
- Friedrich M et al. Nature Cancer 2022 doi: 10.1038/s43018-021-00201-z
- Sankowski R et al. Nature Medicine 2024 doi: 10.1038/s41591-023-02673-1
- Wertheimer T et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01755-7
- Maas-Bauer K et al. Nature Commun. 2024 doi: 10.1038/s41467-024-44703-7
- Velasco Cárdenas RM et al. Nature Immunol 2023 doi: 10.1038/s41590-023-01658
- Zhang YW et al. Nature Cell Biology 2022 doi: 10.1038/s41556-022-00931-x
- Ho J et al. Blood 2022 doi: 10.1182/blood.2022016082
- Rückert T et al. Sci Transl Med. 2022 doi: 10.1126/scitranslmed.abp9675.
- Talvard-Balland N et al. J Clin Invest. 2024 doi: 10.1172/JCI177460.
- Denk D et al. Immunity 2022 doi: 10.1016/j.immuni.2022.09.014
- Schmidt D et al. Cancer Res. 2024 doi: 10.1158/0008-5472.CAN-23-3553
- Nicolas AM et al. Cancer Cell. 2022 doi: 10.1016/j.ccell.2022.01.004
- Grünwald BT et al. Cell 2021 doi: 10.1016/j.cell.2021.09.022.
- Zhang Z et al. Nature Immunol. 2025 doi: 10.1038/s41590-024-02027-0.
- Braun L et al. Cancer Cell. 2025 doi: 10.1016/j.ccell.2025.01.004.
- Vinnakota JM et al. Sci Transl Med. 2024 doi: 10.1126/scitranslmed.adj9672.
- Edwards-Hicks J et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01419.
- Saller BS et al. Immunity 2024 doi: 10.1016/j.immuni.2024.10.012.
- Heim K et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01928-4.
- Gallage S et al. Cell Metab. 2024 doi: 10.1016/j.cmet.2024.04.015.
- Denk D et al. Immunity 2025 doi: 10.1016/j.immuni.2025.02.005
- Gorantla SP et al. Nature Commun 2025 doi: 10.1038/s41467-025-60019-6
Publications based on CRC1479 funding
Maas-Bauer K, Stell AV, Yan KL, de Vega E, Vinnakota JM, Unger S, Núñez N, Norona J, Talvard-Balland N, Koßmann S, Schwan C, Miething C, Martens US, Shoumariyeh K, Nestor RP, Duquesne S, Hanke K, Rackiewicz M, Hu Z, El Khawanky N, Taromi S, Andrlova H, Faraidun H, Walter S, Pfeifer D, Follo M, Waldschmidt J, Melchinger W, Rassner M, Wehr C, Schmitt-Graeff A, Halbach S, Liao J, Häcker G, Brummer T, Dengjel J, Andrieux G, Grosse R, Tugues S, Blazar BR, Becher B, Boerries M, Zeiser R. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nat Commun. 2024 Jan 10;15(1):446. doi: 10.1038/s41467-024-44703-7.
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, Mielke S, Mohty M, Nagler A, Passweg J, Patriarca F, Ruutu T, Schoemans H, Solano C, Vrhovac R, Wolff D, Zeiser R, Sureda A, Peric Z. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024 Jan 3:S2352-3026(23)00342-3. doi: 10.1016/S2352-3026(23)00342-3. Epub ahead of print.
